Embedded Files
DelveInsight's "Vitiligo Pipeline Insight, 2025" report offers extensive analysis on over 18 companies and more than 20 pipeline drugs in the Vitiligo treatment landscape. It features in-depth profiles of Vitiligo pipeline drugs, covering both clinical and nonclinical development phases. Furthermore, it assesses Vitiligo pipeline therapeutics by product category, development stage, delivery route, and molecular structure. It also identifies discontinued pipeline products in this domain.
Stay ahead with the latest insights! Obtain DelveInsight's thorough Vitiligo Pipeline Report to explore emerging treatments, key Companies, and future treatment landscapes @ Vitiligo Pipeline Outlook Report
Key Takeaways from the Vitiligo Pipeline Report
In August 2025, Incyte Corporation disclosed a trial to assess the safety and effectiveness of ruxolitinib cream in pediatric patients with nonsegmental vitiligo.
In July 2025, Clinuvel Inc. conducted the CUV105 study to evaluate the effectiveness and safety of afamelanotide combined with NB-UVB light in vitiligo patients on the body and face compared to NB-UVB light alone.
DelveInsight's Vitiligo pipeline report showcases a dynamic field with over 18 active contributors developing more than 20 pipeline treatments for Vitiligo care.
The top Vitiligo Companies include Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc., and others.
Promising Vitiligo Pipeline Therapies include Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide, and others.
Discover how the Vitiligo treatment paradigm is evolving. Access DelveInsight's in-depth Vitiligo Pipeline Analysis for a closer look at promising breakthroughs @ Vitiligo Clinical Trials and Studies
Vitiligo Emerging Drugs Profile
Afamelanotide: Clinuvel, Inc. Afamelanotide, created by Clinuvel, Inc., is a synthetic analog of alpha-melanocyte-stimulating hormone (α-MSH) intended to boost skin pigmentation in vitiligo patients. It functions by stimulating melanocortin 1 receptors (MC1R) on melanocytes, encouraging melanin synthesis and spread in depigmented skin areas. Afamelanotide is delivered via a subcutaneous implant, providing a systemic method that may improve repigmentation, especially with controlled UV light therapy. Its action targets the core pigment loss in vitiligo, aiming for more even skin tone restoration. The drug is currently in Phase III development for Vitiligo.
VYN201: Vyne Therapeutics Inc. Repibresib is a pan-bromodomain BET inhibitor formulated for local administration as a "soft" drug to tackle conditions involving various inflammatory cell signaling pathways, with minimal systemic exposure. BET proteins are crucial in regulating gene transcription through epigenetic interactions ("reading"). Recent studies have highlighted their role in controlling immune cell activation, such as T cells and B cells, and related inflammatory and fibrotic processes. As epigenetic readers, BET proteins manage the recruitment of transcription factors essential for producing multiple pro-inflammatory cytokines. BET inhibitors could address a variety of immuno-inflammatory and fibrotic diseases by inhibiting pro-inflammatory cytokine transcription, with potential in myeloproliferative neoplastic disorders. Besides showing clinical proof-of-concept in vitiligo, repibresib has consistently lowered pro-inflammatory and disease-related biomarkers and improved disease severity in various preclinical models (via different administration routes). The drug is in Phase II development for Vitiligo.
FB102: Forte Biosciences, Inc. FB102 is a proprietary molecule with broad potential in autoimmune and related conditions. The Company's FB102 program targets key pathways in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors, which are critical regulators of NK cells and specific T cell subsets. Notable reductions in NK cell pharmacodynamic markers of FB102's mechanism were seen, supporting the in vitro and NHP data and FB102's mode of action. A Phase 1 healthy volunteer SAD/MAD study was completed successfully, showing a favorable safety profile. The drug is in Phase I development for Vitiligo.
The Vitiligo Pipeline report provides insights into
The report delivers comprehensive details on firms advancing therapies for Vitiligo, including the cumulative treatments each company is developing.
It reviews diverse therapeutic candidates categorized into initial, intermediate, and advanced development stages for Vitiligo management.
Vitiligo Companies are focused on precision therapeutics with ongoing and paused (inactive or terminated) programs.
Vitiligo Drugs in development, sorted by development phase, administration route, target receptor, single or combined therapy, unique action mechanisms, and molecular category.
Comprehensive examination of partnerships (business alliances and academic ties), licensing arrangements, and funding details to propel future progress in the Vitiligo market.
Get a detailed analysis of the latest innovations in the Vitiligo pipeline. Explore DelveInsight's expert-driven report today! @ Vitiligo Unmet Needs
Vitiligo Companies Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc., and others.
Vitiligo pipeline report assesses the therapeutic potential of pipeline drugs by Route of Administration. Products are grouped under different ROAs, including
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Vitiligo Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Obtain DelveInsight's latest report to gain strategic insights into upcoming Vitiligo Therapies and key Developments @ Vitiligo Market Drivers and Barriers, and Future Perspectives
Scope of the Vitiligo Pipeline Report
Coverage- Global
Vitiligo Companies- Vyne Therapeutics Inc., AbbVie, Teva Branded Pharmaceutical Products R&D, Inc., Jiangsu HengRui Medicine Co., Ltd., Pfizer, Incyte Corporation, Merck Sharp & Dohme LLC, Forte Biosciences, Inc., Dren Bio, Clinuvel Inc., and others.
Vitiligo Pipeline Therapies-Ritlecitinib, Upadacitinib, SHR0302Base gel, PF-07038124 0.01%, AMG 714, AMG 714, ruxolitinib, Cerdulatinib 0.37% gel, Afamelanotide, and others.
Vitiligo Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Vitiligo Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Vitiligo drug development? Find out in DelveInsight's exclusive Vitiligo Pipeline Report-access it now! @ Vitiligo Emerging Drugs and Major Companies
About Us
DelveInsight is a premier market research and consulting firm specializing in healthcare, delivering top-tier intelligence and analysis to guide strategic decisions. Our expert team, with profound knowledge of life sciences and healthcare, provides tailored research services and insights worldwide. Reach out for reliable, precise, and timely data to maintain a competitive edge.
Contact Us
Kanishk
kkumar@delveinsight.com
Page updated
Google Sites
Report abuse